Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

ASLAN Signs up JHL to Provide Process Development for Asthma Treatment

publication date: Nov 14, 2016
ASLAN Pharma of Singapore engaged JHL Biotech, a Taiwan/China CMO, to provide biologic process development services and clinical trial supplies of ASLAN004. ASLAN004 is a fully human monoclonal antibody that blocks the signaling of the IL-4 and IL-13 receptors. Work will start in 2016 in JHL's GMP-certified facility in Zhubei, Taiwan. ASLAN secured worldwide rights to ASLAN004 from CSL Behring in 2014, originally for asthma, though it is also developing the molecule to treat cancer. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital